Comparative study of efficacy and adverse effects of different doses of vaginal misoprostol for cervical ripening 10-12 hours before diagnostic hysteroscopy
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20180893Keywords:
Cervical width, Hysteroscopy, MisoprostolAbstract
Background: Hysteroscopy first described by Panteleoni in 1869 has evolved into a standard procedure for the diagnosis and treatment of intrauterine pathologies such as polyps, fibroids, septae, adhesions, evaluation of abnormal uterine bleeding, evaluation and treatment of infertility, removal of an intrauterine device or foreign body. Present study was carried out to compare the efficacy and complications different doses of vaginal misoprostol for cervical ripening10-12 hours before diagnostic hysteroscopy.
Methods: It was a prospective and interventional, double-blinded randomized comparative study. Sixty women, fulfilling the inclusion criteria, requiring diagnostic hysteroscopy for evaluation of infertility were enrolled. The study subjects randomly received either 200μg (group 1) or 400μg (group 2) of vaginal misoprostol 10-12 hours before hysteroscopy with equal number of subjects in both the groups. Hysteroscopy was performed with a standard rigid 6 mm and 300 hysteroscope. The largest dilator that could be inserted without resistance was recorded as the baseline cervical dilatation. The ease of dilatation was recorded on a 5 point LIKERT scale. Procedural time was measured as time taken from the beginning of cervical dilatation to the visualisation of the uterine cavity.
Results: The mean base line cervical width in group 1 was 6.41±0.29 mm while in group 2 it was 6.43±0.21 mm (p=0.084). In group 1, 26.6% patients had very easy entry, 53.4% had easy entry while in group 2, 30% patients had very easy entry, 43.4% had easy entry. The mean procedural time 35.5±6.9 seconds in group 1 and 33.2±6.8 seconds in group 2 (p=0.212). Adverse effects like abdominal pain, vaginal bleeding, shivering and fever were observed more often in group 2 compared to group 1(p=0.038).
Conclusions: Two hundred microgram of vaginal misoprostol is safer and equally effective as 400 μg for cervical ripening when used 10-12 hours before diagnostic hysteroscopy.
References
Hasen A, Zeynep H, Esra T, Turgut V. Comparison of vaginal misoprostol and dinoprostone for cervical ripening before diagnostic hysteroscopy in nulliparous women. Fertil Sterli. 2015;103:1326-31.
Fard SA, Ebrahimi FS, Montazeri F, Mashrabi O. Diagnostic features and therapeutic consequences of hysteroscopy in women with abnormal uterine bleeding and abortion. Am J Applied Sci. 2012;9:13-7.
Jansen FW, Vredevoogd CB, Ulzen KV, Herman J, Trimbos JB, Trimbos- Kemper TC. Complications in hysteroscopy: a prospective multicenter study. Obstet Gynecol. 2000;96:266-70.
Loffer FD. Complications of hysteroscopy-their cause, prevention, and correction. J Am Assoc Gynecol Laparosc. 1995;3:11-26.
Vilos GA, Vilos EC, King JH. Experience with 800 hysteroscopic endometrial ablations. J Am Assoc Gynecol Laparosc. 1996;4:33-8.
Bastu E, Celik C, Nehir A, Dogan M, Yuksel B, Ergun B. Cervical priming before diagnostic operative hysteroscopy in infertile women: a randomized, double-blind, controlled comparison of 2 vaginal misoprostol doses. Int Surg. 2013 May;98(2):140-4.
El-Khayat W, Elsawah H, Idris O. A double-blind randomized controlled trial of two different doses of misoprostol for cervical priming prior to office hysteroscopy. Middle East Fertil Soc J. 2015 Mar 31;20(1):1-5.
Vahdat M, Kashi AM, Saberifard M, Chaichian S. Determination of the effect of vaginal misoprostol in cervical ripening before the operative hysterocopy in premenopausal women without history of normal vaginal delivery. J Minim Invasive Surg Sci. 2013 Sep;2(4).
Vineeta, K Abhinav, Nagar O, K Richa, N Subrata. A randomized, double-blind, placebo- controlled comparison of sublingual and vaginal misoprostol. IOSR-JDMS. 2015;14(4):49-53.
Bakas P, Hassiakos D, Liapis A, Creatsa M, Konidaris S, Gregoriou O. Misoprostol for cervical ripening before diagnostic hysteroscopy in nulliparous women. Int J Gynecol Obstet. 2012;116(3):263-4.
Tanha FD, Salimi S, Ghajarzadeh M. Sublingual versus vaginal misoprostol for cervical ripening before hysteroscopy: a randomized clinical trial. Arch Gynecol Obstet. 2013;287(5):937-40.
Hua Y, Zhang W, Hu X, Yang A, Zhu X. The use of misoprostol for cervical priming prior to hysteroscopy: a systematic review and analysis. Drug Des Devel Ther. 2016;10:2789-2801.
